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Background: Dystonic cerebral palsy is primarily caused by damage to the basal ganglia and central cortex. The
daily care of these patients can be difficult due to dystonic movements. Intrathecal baclofen treatment is a
potential treatment option for dystonia and has become common practice. Despite this widespread adoption, high
quality evidence on the effects of intrathecal baclofen treatment on daily activities is lacking and prospective data
are needed to judge the usefulness and indications for dystonic cerebral palsy. The primary aim of this study is to
provide level one clinical evidence for the effects of intrathecal baclofen treatment on the level of activities and
participation in dystonic cerebral palsy patients. Furthermore, we hope to identify clinical characteristics that will
predict a beneficial effect of intrathecal baclofen in an individual patient.
Methods/Design: A double blind placebo-controlled multi-center randomized clinical trial will be performed in
30 children with dystonic cerebral palsy. Patients aged between 4 and 25 years old with a confirmed diagnosis of
dystonic cerebral palsy, Gross Motor Functioning Classification System level IV or V, with lesions in the cerebral
white matter, basal ganglia or central cortex and who are eligible for intrathecal baclofen treatment will be
included. Group A will receive three months of continuous intrathecal baclofen treatment and group B will receive
three months of placebo treatment, both via an implanted pump. After this three month period, all patients will
receive intrathecal baclofen treatment, with a follow-up after nine months. The primary outcome measurement will
be the effect on activities of and participation in daily life measured by Goal Attainment Scaling. Secondary outcome
measurements on the level of body functions include dystonia, spasticity, pain, comfort and sleep-related breathing
disorders. Side effects will be monitored and we will study whether patient characteristics influence outcome.
Discussion: The results of this study will provide data for evidence-based use of intrathecal baclofen in dystonic
cerebral palsy.
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Dystonic cerebral palsy
Cerebral palsy (CP) is a group of disorders caused by
non-progressive disturbances that occurred in the devel-
oping fetal or early infant brain. The classification of
cerebral palsy includes the classical neurological terms
for central motor disorders: spasticity, dyskinesia and
ataxia [1,2]. Dyskinesia can be further differentiated into
dystonia and choreoathetosis [2]. Dystonia is described
as an abnormal pattern of posture and/or movement
that is involuntary, uncontrolled, recurring and occa-
sionally stereotyped. These movements can interfere
with daily care and may be painful and uncomfortable.
The dyskinetic form of cerebral palsy, including the
dystonic form, is in most patients caused by lesions in
the basal ganglia. Additional lesions of the central cortex
are found in some cases. This type of brain damage is a
common pattern in asphyxiated infants born at term [3].
Treatment
The results of pharmacological treatment of severe dys-
tonic CP have been rather disappointing. Positive effects
on dystonia with levodopa, anticholinergic drugs or
muscle relaxants including benzodiazepines and baclo-
fen, have been reported by some authors [4,5]. In
addition, Albright and co-workers described an anti-
dystonic effect of intrathecal baclofen (ITB) treatment.
Despite the fact that studies on the effects of ITB on
dystonic cerebral palsy are limited in number and the
level of evidence is low, ITB is now common practice in
the treatment of severe dystonic CP.
Not all patients are eligible for ITB treatment. The
following criteria apply: 1. The etiology is preferably
known; 2. Management of aggravating factors, such as
pain and discomfort, should be optimal; 3. Other treat-
ment options should have been explored. Oral pharma-
cological treatment with levodopa, anticholinergic drugs
or muscle relaxants including benzodiazepines and bac-
lofen must have been attempted and must have resulted
in high oral dosages with either unacceptable side effects
or insufficient efficacy; 4. The movement disorder
should be so severe that it interferes with activities of
daily life or quality of life; 5. Treatment goals should be
clear and applicable and, to avoid disappointment, it is
important that patients and parents understand these
goals; 6. Patients and parents should be motivated and
able to adhere to the requirements of treatment, such as
the frequent pump fillings and checkups in the out-
patient clinic; 7. Patients should have sufficient body size
to allow pump implantation [6].
Objectives
The primary objective of the present study is to show
whether ITB treatment improves activities of andparticipation in daily life (for example dressing, transfer,
sitting in a wheelchair, hygienic care, speech) in dystonic
CP patients. Certain patient characteristics, such as the
location and severity of MRI lesions and Gross Motor
Functioning Classification Score (GMFCS) level, might
influence the effects of ITB treatment in patients with
dystonic CP. Therefore, we will study whether individual
patient characteristics (GMFCS, gender, age, MRI find-
ings and co-medication) influence outcome and could
be used in determining the indication for ITB in future
patients. A secondary objective is to provide evidence
for the effect of ITB on the level of body functions. The
relevant clinical questions to be addressed are: 1. Does
ITB decrease dystonia? 2. Does ITB decrease spasticity
in dystonic patients? 3. Does ITB decrease pain? 4. Does
ITB increase comfort? 5. Does ITB influence screening
results of sleep-related breathing disorders? 6. What are
the side effects of ITB?
Methods/Design
Study design
The design of the study is a double blind placebo-
controlled multi-center randomized clinical trial. It will
be conducted in the VU University Medical Center
(VUMC) in Amsterdam and the Maastricht University
Medical Center (MUMC) in Maastricht (both in the
Netherlands). The Medical Ethical Committee of the VU
University Medical Center approved the study. In both
centers local practicability was granted subsequently.
Subjects will be included over a period of two and a half
years and they will participate in the study for one year.
Figure 1 shows the flow scheme for subjects and timing
of measurements throughout the study.
Participants
Thirty subjects will be recruited from the outpatient
clinics of the pediatric neurology and pediatric rehabili-
tation departments of the VUMC and the MUMC.
Table 1 shows the inclusion and exclusion criteria. We
selected ages between 4 and 25 years old because older
patients often show secondary complications, such as
contractures, that could introduce greater variation into
both the effects of treatment and treatment goals. Fur-
thermore, to achieve a homogeneous patient group, only
GMFCS IV and V (non-walkers) will be included. All
patients and/or their caregivers will sign an informed
consent form before participating in the study.
Sample size calculation
We will use goal attainment scaling (GAS) as our pri-
mary outcome measure. The within group change for
the placebo group is anticipated to be 0, with a standard
deviation (SD) of 8.5. For the intrathecal baclofen group,
the within group change is anticipated to be 12.5, with a
Figure 1 Flow chart subjects.
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difference in means using a two-tailed independent sam-
ples t-test and a significance level of 5%, a total of 13
subjects per group will be needed.
In a previous study in the VU University Medical Cen-
ter, 4 infections occurred in 34 pump implantations [7].
Ward and coworkers reported pump removal in 5.9% of
the cases with infections following implantation [8]. Ex-
trapolating these numbers, inclusion of 30 patients is ex-
pected to lead to 3.5 infections and 1.2 pump removals.
To prevent the study from becoming underpowered, due
to unexpected protocol violations or subject dropout
due to complications other than those related to intra-
thecal baclofen treatment, we will include 15 subjects
per group.
Intervention
Included subjects will be randomized in two groups.
Group 1 will receive placebo treatment via an implanted
micro-infusion pump for three months. Group 2 will
receive ITB treatment via an implanted micro-infusionTable 1 Summary of inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Dystonic cerebral palsy • Contra-indications for general
anesthesia
• GMFCS IV or V • Contra-indications for baclofen
• Eligible for ITB treatment using
criteria of common practice
• Oral pharmacological treatment
is sufficient
• Lesions on MRI (cerebral white
matter, basal ganglia, central cortex)
• Inadequate knowledge of
Dutch language
• Aged 4 to 25 years old • Deep brain stimulation
• Able and willing to complete
study protocol
• Ventriculoperitoneal drain
• Consensus about inclusion • Other disorders interfering with
treatmentpump for three months. In our opinion, it is unethical to
continue placebo treatment for more than three months.
If interim analysis shows that subjects in one of the
groups have significant disadvantages compared to the
other group, the study will be prematurely terminated.
On the other hand, we know from experience that
dosages for some patients are still being modified three
months after starting treatment. As a consequence, the
effect of treatment in these patients may not yet be opti-
mal, which may then result in no detectable effect of
ITB treatment at that point. We will try to reduce this
possible effect through frequent dose modification.
Patients will be seen once or twice weekly to increase
their dosage, until either a stable dosage or a maximal
dosage of 800 μg/day is achieved.
Subjects will be assessed at three months and the
effect of treatment in the two groups compared. Since
determining the most beneficial pump setting can take
more than three months and because the initial effect
may recede in some cases, all subjects will receive subse-
quent ITB treatment for nine months. Following this
9 month period, clinical evaluation will be performed in
order to determine long-term effects (see Figure 1. Flow
Chart of Subjects).
Dosage
Patients with dystonia seem to require larger ITB doses
than the doses used to treat spasticity [9]. Albright and
colleagues noticed a change in dystonia only after 4 days
of continuous infusion [10]. The effective dose of ITB
was in the range of 350 to 750 μg/day [9-11]. Since a
screening period will not be included, we do not know
how subjects will respond and which dose will be suffi-
ciently effective. Therefore, the starting dosage will be
50 μg/24 h.
Dosage can be increased by 10-20% daily. When sub-
jects are discharged from the hospital following pump
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every two weeks for dosage modification. After three
weeks of increasing dosage, with disappearance of the ef-
fect of the increase, daily boluses will be administered to
a maximum of four times a day, with a minimal interval
of four hours. For the blinded part of the study, a max-
imum dosage of 800 μg/day will be administered. This is
a reasonable estimation of the maximal dosage after
three months. Since treatment during the study is
blinded, the physician in charge of regular follow-up
after pump implantation, including pump filling and
dosage adjustments, will be unaware of the subject’s allo-
cated group. To provide optimal treatment, pump set-
tings will be individually altered to the extent that the
physician would consider necessary, based on the find-
ings of physical examination and parental and patient
interview, as were the patient not participating in the
study. As a consequence, the pump settings of subjects
in the placebo group will be altered as if the patient was
receiving ITB treatment.
Lack of response to ITB can be caused by pump or
catheter dysfunction. Placebo treatment may also cause
lack of effect and for this reason no action will be taken
during the first three months of the study in cases where
pump or catheter dysfunction would normally be sus-
pected. An exception will be made when the condition
of the patient requires otherwise, such as in the case of
signs of withdrawal. One week after pump implantation,
all patients will undergo X-ray of the spine to determine
the position of the catheter tip. The catheter should be
placed approximately at the fourth cervical level, and at
least above the level of Th1.
Outcome measures
Outcome measurements are defined on the levels of the
International Classification of Functioning, Disability and
Health (ICF) model of the World Health Organization
(WHO). We distinguish the level of activities and partici-
pation and the level of body functions. Body functions are
the physiological and psychological functions of body
systems. Activities are defined as the execution of a task
or action by an individual. Participation is involvement in
a life situation [12].
Primary outcome measure
The primary outcome measurement will be on the level
of activities and participation. Goal attainment scaling
(GAS) will be used to measure the effect of ITB treat-
ment. Using GAS, achievement of individual set goals
can be quantified. This method was introduced for
assessing outcomes in mental health settings and has
been used in many other areas [13,14]. Each subject has
their own outcome measure, but statistical analysis is
possible because they are scored in a standardized way.This procedure is time-consuming and requires about
45 minutes per child [15,16]. However, after the scale is
constructed, it should be possible to score a patient
within 10 minutes [17].
The procedure includes the following aspects:
1) Identification of goals:
Three main problems of daily care and function will
be determined by caregivers. Goals will be set for
these problems with the help of the team to ensure
that goals are achievable. Goals should be specific,
measurable, attainable, realistic and timely (SMART)
[13,14]. The target activity, specific support and time
period should be specified and performance should
be quantified using distance, frequency or time taken
to accomplish a task [14].
2) Weighing of goals:
Some goals will be more important for subjects than
others [13]. Goals can be assigned a weighing score
by caregivers and a difficulty score by the team [14].
We chose not to assign weighing scores since the
weighted and unweighted scores are closely correlated
[18]. A value of 1 is applied to ‘weight’ in the formula
described below.
3) Definition of expected outcomes:
Several approaches are described in literature,
varying from 5 to 7 point scales [14,15]. We will use
a 6 point scale ranging from −3 to +2, since we wish
to include both the possibility of partially achieving
the set goal and to avoid a bottoming effect. Baseline
scores will be allocated as −2. If the subject achieves
the expected level, this is scored as 0. If a subject
does not achieve the expected level but shows
improvement, this is scored as −1. If they achieve
more than the expected outcome, this is scored as +1
for somewhat more and +2 for much more. We chose
to add a score of −3 in case of deterioration. Each goal
level will be defined by the investigator so as to be as
objective and observable as possible [13].
4) Scoring goal attainment:
For each assessment, one assessor will make a
standardized video recording during trials for each
of the three functional ability goals. The recording
procedure will be identical for all measurements.
Another assessor, blinded for group allocation, will
rate the subject’s performance from the video
recordings. Although the GAS only simulates the
subject’s own functional setting, parents were
convinced that the outcome of scaling was
representative of their own setting [19].
Goal attainment scores will be recorded at baseline,
after three months of blinded treatment and after nine
months of ITB treatment. Goal attainment change
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score from the outcome score. Subjects who achieve a
GAS T-score >50 achieved their goals [8]. Clinical rele-
vance will be defined as an improvement of at least two
points in at least one of the three goals [19].
A single aggregated score (T-score) can be produced
by a standardized mathematical formula: Overall GAS =
50+ 10∑(wixi) / √((1-ρ) ∑wi
2 + ρ(∑wi)
2); Wi is the weight
assigned to the goal, xi is the numerical value achieved
(between −3 and +2), ρ (rho) is the expected correlation
of the goal scales, which is normally 0.3 [13,14].
Secondary outcome measures
Dystonia
Videos of all patients will be made using the video
protocol described by Monbaliu et al. [20]. Blinded ther-
apists or physicians will assess all videotapes and rate
dystonia using the Barry-Albright dystonia (BAD) scale
and the Dyskinesia Impairment Scale (DIS).
The BAD scale is a five point ordinal severity scale to
assess secondary dystonia in eight body regions (eyes,
mouth, neck, trunk, each upper and lower extremity)
[21]. Raters score dystonia as none, slight, mild, moder-
ate or severe. A reduction of 25% or more, in compari-
son with the baseline score, is considered clinically
significant. In our experience, interrater variability is
high, but BAD scores are generally accepted as a mea-
surement of dystonia and are widely used to assess
dystonia.
Recently, a new instrument to measure dystonia in
dyskinetic CP became available, the DIS [20]. It consists
of two subscales: dystonia and choreoathetosis. Scoring
is carried out in 12 body regions all in two conditions
(rest and activity). Both duration and amplitude are
evaluated. Since this is a new instrument, we will use the
DIS in addition to the BAD.
Electromyography
The DIS has no external validation. We decided that
Surface Electromyography (EMG) might provide an im-
pression of muscle activity level underlying dystonia.
Therefore, surface EMG measurements will be carried
out to determine mean EMG activity in individually
determined muscle groups and in multiple conditions
such as rest and during activities.
Spasticity
The soleus Hoffmann-reflex (H-reflex) represents excit-
ability of the neural components of the stretch reflex arc
[22]. The H/M-ratio of the H-reflex represents an in-
creased excitability of soleus motor neurons. The H/
M-ratio is increased in subjects with spasticity due to
various origins, [23] and it has been shown that the
Hmax decreases significantly after ITB administration inchildren with spastic cerebral palsy when compared with
baseline measurements. This represents a decrease in
motor neuron excitability. Furthermore, the response ap-
pears to be dose-dependent [22]. Although not all chil-
dren tolerate the measurements, feasibility of the H-reflex
was 93% in a study by Hoving and co-workers [22].
For clinical assessment of spasticity in children with
central motor disorders, the spasticity test (SPAT) is
used during standard physical examination. When using
the SPAT, we will follow a standardized protocol as de-
scribed in the guideline for standard physical examin-
ation of children with central motor disorders [24,25].
The difference between the range of motion and the
angle of catch will be used as the outcome measure for
spasticity [26]. The test takes approximately 5 to 8 mi-
nutes per limb to perform [25]. This test might be diffi-
cult to perform in children and adolescents with severe
dystonia and its usefulness will become evident during
the study.Pain and comfort
Parents will score pain and comfort on a visual analogue
scale (VAS). The VAS is a straight 10 cm long horizontal
block consisting of 10 smaller blocks with anchor points
at 0 and 10. For pain, a score of 0 represents ‘no pain’
and a score of 10 represents ‘the worst possible pain’.
For comfort, a score of 0 will represent being ‘very un-
comfortable’ and a score of 10 is having ‘no problems at
all’. If patients are able to indicate their mood, it will be
scored by pointing out the applicable happy face, with
choices of six faces ranging from very happy to very sad.Sleep-related breathing disorders
Children with CP have a higher risk of sleep-related dis-
orders than typically developing children [27]. Bensmail
et al. showed that patients with severe spasticity due to
spinal cord injury and multiple sclerosis, treated with
ITB by bolus administration, showed an increased re-
spiratory disturbance index (the number of apneas/
hypopneas per hour of sleep) [28,29]. Polysomnography
is the gold standard when measuring sleep-related breath-
ing disorders (SRBD). However, this time-consuming and
burdensome diagnostic test is not practical for children
participating in research [30]. A subscale of the Pediatric
Sleep Questionnaire was developed to measure SRBD.
This scale consists of 22 items and can be completed in
five minutes. Sensitivity and specificity are high (81% and
87%). The scale is positive for a high risk of SRBD when
there are 8 or more positive answers to the 22 question
items (≥33%) [30]. As the burden of a questionnaire is low
for the patients and their families, as compared to poly-
somnography, we will use this questionnaire to determine
if ITB changes the risk of SRBD.
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For classification of the severity of motor abilities we will
use the GMFCS [31,32] and the Manual Ability Classifi-
cation System (MACS) [33,34]. GMFCS and MACS clas-
sification will be scored at baseline, 3 months and at
twelve months. In a study by Voorman and co-workers,
74% of children with CP had restrictions in communica-
tion [35]. Since many children with severe CP (GMFCS
IV and V) cannot speak, assessment of language abilities
cannot be based on speech production. In addition,
language comprehension skills are difficult to assess in
children with severe CP. Therefore, we will use the
Computer-Based Instrument for Low motor Language
Testing (C-BiLLT) to measure comprehension of spoken
language at baseline. The validity of this instrument has
been tested [36]. We do not expect changes in outcomes
on the C-BiLLT with ITB treatment since comprehen-
sion of spoken language is highly correlated with cogni-
tion, and cognition is not effected by ITB treatment.
We will use the outcome of the C-BiLLT as a patient
characteristic.
Magnetic resonance imaging (MRI) will be used to
classify the severity of damage to the gray matter struc-
tures (cortex and basal ganglia) and white matter (loss of
white matter and gliosis). The severity of brain damage
on MRI can be classified in three groups; mild, moderate
and severe. The mild pattern includes involvement of
nucleus lentiformis and ventro-lateral thalamus, the
moderate pattern includes additional involvement of the
peri-central region and the severe pattern includes add-
itional involvement of the entire thalamus and hippo-
campus. In the mild and moderate damage groups,
infants suffer from the dyskinetic form of cerebral palsy,
whereas the severe type of damage frequently produces
purely spastic paresis [3]. MRI studies of the brain are
necessary to confirm the diagnosis of cerebral palsy. If
MRI studies have been conducted previously, these stud-
ies will be critically assessed. If the quality is good, the
MRI will be accepted and no further imaging is needed.
If the quality of the MRI images is poor, the patient will
undergo a new MRI including diffusion tensor imaging
(DTI). If a patient had not yet undergone a MRI, one
will be made including DTI. Adding DTI images to a
regular MRI scan will require an extra scanning time of
approximately four minutes. In this patient category
MRI imaging has to be done under general anesthesia,
since dystonic movements interfere with MRI quality.
Other study parameters
To assess the safety of ITB treatment, side effects and
complications will be closely monitored. The com-
plication rate will be calculated by dividing the number
of complications by the duration in years of pump
implantation.Functional abilities at baseline will be assessed by the
Paediatric Evaluation of Disability Inventory (PEDI) and
will be repeated after three and twelve months. The
PEDI was developed for children from six months to
seven and a half years of age and assesses skills in mobil-
ity, self-care and social function. It can also be used for
older children if their functional abilities are expected to
be below the level of a child of seven and a half years
old. The functional scales indicate if children with dis-
ability are able or unable to perform certain activities.
Separate measures assess the degree of caregiving assist-
ance and equipment modification that is needed to
accomplish complex functional skills. Scores on the care-
giver assistance scale are noted on a range from independ-
ent to maximal assistance and modification scores are
scored as none, child-oriented, rehabilitation-oriented or
extensive [37,38]. The PEDI will be administered through
direct assessment by a therapist.
Randomization, blinding and treatment allocation
Subjects will be randomized in two groups by block
randomization. Randomization will be done by the phar-
macies of the VUMC and the MUMC. The pharmacist
will be the only holder of the code for randomization. In
case of emergency, the code will be accessible 24 hours
per day and 7 days per week via either the pharmacist of
the VUMC or MUMC or by opening a sealed envelope
containing the subject’s group, available at the depart-
ments concerned. Allocation will be concealed, and the
researchers, assessors and the physician responsible for
pump filling will be blinded.
Premature termination
Withdrawal of individual subjects
Subjects can end participation in the study at any time
without providing a reason and without consequences
for their future treatment in the clinic. The investigator
can decide to withdraw a subject from the study for
urgent medical reasons. Subjects withdrawn from the
study will continue their regular follow-up outside of the
study protocol. Subjects will be replaced if they with-
draw before pump implantation has taken place. Sub-
jects who withdraw after pump implantation has taken
place will not be replaced. With subject agreement, a
final assessment will take place before definite ending of
participation. These subjects will not be included in the
analysis but we will present a fact sheet including their
information.
Data safety monitoring board
A data safety monitoring board will be formed and will
meet periodically to review aggregate and individual
subject data related to safety, data integrity and overall
conduct of the trial. They will assess the risk/benefit
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pending upon this assessment, the board will provide
recommendations to continue, adapt or terminate the
trial.Statistics
Descriptive statistics
Patient characteristics will be described. Gender distri-
bution will be compared between the ITB and placebo
group using a Chi-square test. Mean age between the
ITB and placebo group will be compared using an inde-
pendent samples t-test. Means and standard deviation
(SD) of the PEDI scores, C-BiLLT scores, GAS t-score,
BAD score, SPAT score and mean EMG activity at base-
line will be tabulated. Means and SD of the GAS t-score,
BAD score, DIS score, SPAT score and mean EMG activ-
ity at follow up will be separately tabulated per group.Univariate analysis
The GAS t-scores, BAD score, SPAT score and EMG
activity in the placebo and ITB group will be compared
using an independent samples t-test. If the assumption
of normality appears not to be valid, the non-parametric
Mann–Whitney test will instead be used. A p-value of
0.05 is considered statistically significant for this primary
analysis. To assess within-group changes in means be-
tween follow-up times and baseline GAS t-scores, BAD
score, DIS score, SPAT score and EMG activity, a paired
t-test or non-parametric Wilcoxon test will be used (de-
pending on whether the normality assumption is valid).
In these analyses, a p-value of 0.05 is considered to be
statistically significant.Multivariate analysis
A multivariate analysis will be used to determine the
effect of ITB treatment (primary: functional outcome;
secondary: dystonia and the interaction with GMFCS,
MACS, MRI classification and use of co-medication).Discussion
We anticipate that the results of this study will allow
evidence-based use of intrathecal baclofen in dystonic
cerebral palsy.
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